Abbott Laboratories (ABT)

77.97
NYSE : Health Technology
Prev Close 80.06
Day Low/High 77.69 / 80.00
52 Wk Low/High 56.81 / 80.49
Avg Volume 6.53M
Exchange NYSE
Shares Outstanding 1.76B
Market Cap 140.62B
EPS 1.30
P/E Ratio 61.11
Div & Yield 1.28 (1.45%)

Weekly Roundup

Stocks finish week sharply lower on worries over global economic growth slowing after earlier surging on Fed's more accommodating stance.

Markets Open Lower Friday, a Check on CVS Health After Last Night's Interview

We are encouraged with CVS Health's plans to fix what has hurt the company and we reiterate that the stock is still inexpensive.

Trimming Abbott Labs Before the Closing Bell

As much as we continue to believe in the company and its strong organic growth trends, discipline calls for us to lock in some of our big gains.

Abbott Hosts Conference Call For First-Quarter Earnings

Abbott Hosts Conference Call For First-Quarter Earnings

ABBOTT PARK, Ill., March 20, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2019 financial results on Wednesday, April 17, 2019, before the market opens.

Abbott Announces CE Mark For Alinity™ M Diagnostics System And Assays, The Latest In Molecular Technology, To Help Deliver Critical Test Results And Benefits To Patients

Abbott Announces CE Mark For Alinity™ M Diagnostics System And Assays, The Latest In Molecular Technology, To Help Deliver Critical Test Results And Benefits To Patients

- Alinity m will allow labs to meet the growing demand for infectious disease testing by offering increased efficiency and market-leading speed and accuracy

New Data For Abbott's HeartMate 3™ Highlights Unparalleled Performance Of Industry's Leading Heart Pump

New Data For Abbott's HeartMate 3™ Highlights Unparalleled Performance Of Industry's Leading Heart Pump

- New MOMENTUM 3 data show the best outcomes seen in a randomized controlled clinical trial for left ventricular assist device (LVAD) therapy

New Late-Breaking Analyses From Landmark COAPT™ Trial Show Benefits Of Abbott's MitraClip™ Device

New Late-Breaking Analyses From Landmark COAPT™ Trial Show Benefits Of Abbott's MitraClip™ Device

- New data presented and simultaneously published in the Journal of the American College of Cardiology show treatment with MitraClip resulted in significant and sustained long-term quality-of-life improvements compared to medical therapy

Weekly Roundup

Strong earnings boost shares in a rebound week for stocks.

Updates on 4 Portfolio Names

These stocks are moving on recent headlines.

Abbott Receives FDA Approval For Expanded Indication For MitraClip™ Device

Abbott Receives FDA Approval For Expanded Indication For MitraClip™ Device

- The world's first minimally invasive mitral valve repair device now approved to help difficult-to-treat heart failure patients with clinically significant secondary mitral regurgitation

Weekly Roundup

With China reducing its GDP forecast and Europe's central bank growing cautious, markets turned lower this week.

Abbott Laboratories Takes Over #66 Spot From Synopsys

Abbott Laboratories Takes Over #66 Spot From Synopsys

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Abbott Laboratories has taken over the #66 spot from Synopsys Inc , according to ETF Channel. Below is a chart of Abbott Laboratories versus Synopsys Inc plotting their respective rank within the S&P 500 over time (ABT plotted in blue; SNPS plotted in green): In forming the rank, the analyst opinions from the major brokerage houses were tallied, and averaged; then, the underlying components were ranked according to those averages.

Late-Breaking Data Presentations At ACC 2019 Highlight Abbott's Leading Cardiovascular Portfolio

Late-Breaking Data Presentations At ACC 2019 Highlight Abbott's Leading Cardiovascular Portfolio

- Five late-breaking data presentations at ACC 2019 showcase the breadth and depth of Abbott's cardiovascular portfolio

Abbott's Latest Diagnostics Technology, Alinity, Selected By Regional Medical Laboratory, Inc. To Deliver Benefits To Hospitals And Patients

Abbott's Latest Diagnostics Technology, Alinity, Selected By Regional Medical Laboratory, Inc. To Deliver Benefits To Hospitals And Patients

Regional Medical Laboratory, Inc., which is part of the Ascension network, partners with Abbott, the global health leader, to advance lab capabilities and help improve health outcomes

Weekly Roundup

Markets end volatile week little changed in spite of failed North Korea summit, and congressional testimony from Powell, Lighthizer and Cohen.

Abbott To Present At Barclays Global Healthcare Conference

Abbott To Present At Barclays Global Healthcare Conference

ABBOTT PARK, Ill., Feb.

Weekly Roundup

We made several trades this week as markets edged higher on optimism over a U.S.-China trade deal.

Abbott Declares 381st Consecutive Quarterly Dividend

Abbott Declares 381st Consecutive Quarterly Dividend

ABBOTT PARK, Ill., Feb.

New Real-World Evidence Analysis Of Nearly Half A Million FreeStyle® Libre System Users Shows Higher Rates Of Scanning Improves Glucose Control

New Real-World Evidence Analysis Of Nearly Half A Million FreeStyle® Libre System Users Shows Higher Rates Of Scanning Improves Glucose Control

- Data presented at ATTD confirms previous analyses that higher rates of scanning with the FreeStyle Libre system are strongly associated with improved glucose control

Abbott And Novo Nordisk Enter Partnership To Provide Integrated Digital Solution To People With Diabetes Using Insulin

Abbott And Novo Nordisk Enter Partnership To Provide Integrated Digital Solution To People With Diabetes Using Insulin

Collaboration will enable insulin data to be shared between Novo Nordisk connected insulin pens and digital health tools compatible(i) with FreeStyle Libre portfolio of products

Abbott Introduces The World's Most Sensitive Rapid Diagnostic Test, Determine™ HBsAg 2, To Accelerate Hepatitis B Care

Abbott Introduces The World's Most Sensitive Rapid Diagnostic Test, Determine™ HBsAg 2, To Accelerate Hepatitis B Care

- New point-of-care rapid test identifies and helps make effective care more accessible for millions of people living with hepatitis B, in support of World Health Organization (WHO) hepatitis targets

Trading Notes for Select Stocks

Trading Notes for Select Stocks

Here's my take on a list of stocks I've been watching.

Weekly Roundup

Markets continued to move higher this week.

How to Fatten Up Your Portfolio By Investing in the Obesity Epidemic

How to Fatten Up Your Portfolio By Investing in the Obesity Epidemic

As the U.S. and the world grow fatter, some investors are seeing green as they bulk up on stocks of companies on the front-lines of this 21st century Battle of the Bulge.

Weekly Roundup

Markets pulled back this week following a strong January.

Weekly Roundup

It was a big week for earnings and Jerome Powell's Fed.

7 Best Investment Apps for Your Portfolio in 2019

7 Best Investment Apps for Your Portfolio in 2019

These mobile investment apps can get you up and trading fast, sometimes with no trading fees.

Weekly Roundup

It was another volatile week on Wall Street.

Shares of Abbott Laboratories Poised for Upside Breakout

Shares of Abbott Laboratories Poised for Upside Breakout

ABT is pointed up after trading in a choppy range since October.

Caterpillar, PG&E, Nio: 'Mad Money' Lightning Round

Caterpillar, PG&E, Nio: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Caterpillar, PG&E, Nio, Visa, Tenneco and more.

TheStreet Quant Rating: A- (Buy)